J&J announces data to support boosting its single-shot COVID-19 vaccine

J&J announces data to support boosting its single-shot COVID-19 vaccine

New data shows that a booster dose of the Johnson & Johnson COVID-19 vaccine generated a rapid and robust increase in spike-binding antibodies, nine-fold higher than 28 days after the primary single-dose vaccination, among clinical trial participants.

This was revealed in a statement released by J&J on Wednesday, 25 August 2021, where the company announced data supporting the use of its COVID-19 vaccine as a booster shot for people previously vaccinated with the single-shot Johnson & Johnson vaccine.

Johnson & Johnson’s data is based on two clinical trials conducted in the U.S. and Europe. As a result, the company submitted their results to the preprint database medRXIV on 24 August 2021, which still needs to be peer-reviewed.

However, Mathai Mammen, M.D., PhD, Global Head, Janssen Research & Development, Johnson & Johnson, said, “We have established that a single shot of our COVID-19 vaccine generates strong and robust immune responses that are durable and persistent through eight months. With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine.”

Mammen adds that the company is now looking forward to discussion with public health officials regarding a potential strategy for their Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.

The company is engaging with the U.S. Food and Drug Administration (FDA), U.S. Centers for Disease Control and Prevention (CDC), European Medicines Agency (EMA) and other health authorities regarding boosting with the Johnson & Johnson COVID-19 vaccine.

Independent researchers have told NPR the finding would probably support giving people boosters with the Johnson & Johnson vaccine. But they noted that with 17 volunteers, the study was relatively small. In addition, they claimed the study does not appear to have tested whether the increased antibodies would necessarily translate into increased protection in the real world.

Johnson & Johnson states that it continues to generate and evaluate data from ongoing trials and emerging real-world evidence.

What are your thoughts on the matter? Share your views in the comment section below.

Leave a Reply

Your email address will not be published. Required fields are marked *

Complete Wellness For You

 Medical Advancements, News & Interviews

Congenital disabilities

Congenital disabilities, what you need to know about

Probing into congenital disorders, Newcastle-based gynaecologist and obstetrician Dr Peter Chukwu elaborates that birth defects can be defined as structural or functional anomalies that occur during intrauterine life. He says, “These conditions develop prenatally and may be identified before or at birth or later in life.”

Read More »

Brush up on your Haemophilia knowledge

“Haemophilia is classically inherited and can’t be transmitted like the common cold or flu. Both haemophilia A and B are more prevalent in males than in females, resulting from a genetic defect in the X chromosome.”

Read More »

Tuberculosis, the bacterial disease, what you should know

“At a local level, the global health organisation notes TB incidence and case-fatality rates have increased threefold in South Africa over the ensuing decade, with more than 400 000 cases requiring treatment annually. Therefore, it is essential to understand what TB is, thereby minimising your chances of infection.”

Read More »

Request Your Consultation Online